Buchang announces dividend for FY2018

Buchang held its Annual Shareholder Meeting in June 2019, where it approved the payment of its FY2018 dividend and announced a bonus share issue. Details of these are set out below:

– Dividend: FY2018 profit distribution plan of RMB1.614 per share (before tax)
– Bonus Share: the issuance of 3 new shares for every 10 existing shares held

The budget for 2019 was also approved, with target revenue and net profit for FY2019 set at RMB 15.32 billion (up 12.1% from 2018’s 13.66 billion) and RMB 2.04 million (up 6.7% from 2018’s 1.91 billion) respectively.


About Buchang

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

Daijia helped the 2nd Hospital of Jilin University pass the “Interconnected Hospital Information Test”

China’s National Health Commission recently announced results for the Interconnected Hospital Information test and the Second Hospital of Jilin University passed the four-level assessment with a high score 91.17. Daijia HealthUnion implemented a full hospital IT system based on its HiUp 2.0 system, which helped the hospital pass the test. The Second Hospital of Jilin University is a leading Class III hospital in both Jilin Province and north-eastern China with 2,789 beds.

The hospital’s full IT solution is based on internationally accepted “Healthcare Information Exchange” technology. Daijia’s HIE platform allows cooperation between clinical departments, the hospital’s management team, and the IT department to develop a suite of IT solutions including an information integration platform, clinical data centre, clinical research data centre, operating data centre, EMR, CDSS, ETL tool, BI, management tools, patient applications, etc, all within 18 months.

Monitoring Interface of Daijia’s HiUp2.0


About Daijia HealthUnion

Daijia HealthUnion is a leading healthcare IT company in China. Daijia can provide health information products and solutions including: imaging solutions, diagnostic platforms, data solutions, telemedicine solutions, cloud imaging solutions, patient applications and others.